- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
366
under hydrostatic pressure (Hernandez et al., 2000). In cultured human optic nerve astrocytes TGFb2 increased expression of collagen type 4 and transglutaminase 2 (Fuchshofer et al., 2005) so the alterations in TGFb2 levels and TGFb receptors noted above are consistent with enhanced expression of matrix protein. Interestingly, TGFb2 induces expression of TGM2 and fibronectin in cultured human trabecular meshwork cells (Zhao et al., 2004) and ECM proteins in organ culture. Therefore, alterations in TGFb signaling in POAG may affect not only the ONH but the aqueous outflow facility as well.
There are also alterations in the bone morphogenic protein (BMP) signaling pathways in glaucomatous astrocytes. BMPs are similar to TGFB in that the BMP receptors are coupled to SMAD proteins (SMAD1, SMAD4, SMAD5) and induce transcriptional activity (Zode et al., 2007). BMP4 is secreted by ONH astrocytes (Wordinger et al., 2002) and is upregulated 2.3-fold in cells from glaucoma donors (Hernandez et al., 2002). SMAD6 is one of the SMADs that inhibits the transcriptional activity of SMADs 1 and 4 (Chen et al., 2004). Expression of SMAD6 is upregulated in glaucomatous astrocytes (Hernandez et al., 2002) so that the elevated expression of BMP4 by glaucomatous ONH astrocytes may not affect these cells, but could affect the neighboring lamina cribrosa cells that also have BMP4 receptors (Zode et al., 2007).
Oxidative stress in ONH astrocytes
Hydrogen peroxide (H2O2), which is abundantly produced during CNS injury and ischemia, promotes pathological excitatory amino acid release and swelling of reactive astrocytes (Hirrlinger et al., 2000). The antioxidant glutathione (GSH) plays an important role in protecting the mitochondrial electron transport chain (ETC) from damage by oxidative stress in astrocytes and neurons. GSH represents the major CNS thiol and is essential for prevention of oxidative stress. In the CNS, astrocytes use either glutamate or glutamine as precursors for GSH synthesis. Damage to the axons of RGC in glaucoma may
occur by production of reactive oxygen species (ROS) by reactive astrocytes (Tezel, 2006). Our microarray data indicates that glaucomatous astrocytes may counteract the effects of ROS on RGC axons by increasing production of GSH through increased expression of glutamatecysteine ligase (GCL), the rate-limiting enzyme of the synthesis of GSH (Hernandez et al., 2002). GSH plays an important role in protecting the mitochondrial ETC from damage by oxidative stress in astrocytes and neurons. The antioxidant enzyme mitochondrial superoxide dismutase (SOD2) catalyzes the dismutation reaction involving the conversion of superoxide anion (O2 ) to oxygen (O2) and H2O2. Data from our laboratory shows that in glaucomatous astrocytes increased SOD2 expression (Fig. 8) is under transcriptional regulation of NF-kB via the androgen receptor (AR) (Agapova et al., 2006b).
Human OHN astrocytes treated with HNE showed immediate decreased cellular levels of GSH, which in turn induced expression of GCLC, the rate-limiting enzyme in the synthesis of GSH (Malone and Hernandez, 2007). The strong induction of GCLC and new synthesis of GSH after a 24 h recovery from the HNE treatment indicates that ONH astrocytes can manage oxidative stress. These results are consistent with similar experiments performed with Madin-Darby canine kidney II cells (MDCK II) (Ji et al., 2004), transformed human bronchial epithelial (HBE1) cells (Dickinson et al., 2002), and rat astrocytes (Ahmed et al., 2002).
Glaucomatous ONH astrocytes compared to normal ONH astrocytes have lower basal levels of GSH, which may imply a compromised oxidation– reduction system or a depleted antioxidant response in the glaucomatous optic nerve (Malone and Hernandez, 2007). This observation is consistent with a study that assessed the levels of plasma GSH in patients with untreated POAG and found lower levels of circulating GSH in glaucoma patients when compared to control subjects (Gherghel et al., 2005). However, unlike the normal ONH astrocytes, glaucomatous ONH astrocytes exhibited increased levels of GSH immediately following treatment with HNE. This result may be consistent with findings by Ferreira
367
Fig. 8. Expression of SOD-2 in the monkey optic nerve head. (A) Immunofluorescent staining shows SOD-2 (red) localized to abundant mitochondria in the axons of the RGC in the lamina cribrosa (LC) (arrows) and very few in GFAP+ astrocytes (green) in a normal monkey eye. (B) In experimental glaucoma (ExpG), there is an increase in SOD-2 immunoreactivity in astrocytes (arrows) and a marked decrease in axons in the nerve bundles. A and B: Magnification bar ¼ 35 mm. For methods see (Agapova et al., 2003a). (C) Relative amount of SOD2 mRNA in normal and glaucomatous ONH astrocytes measured by quantitative RT-PCR. Bar graphs represent relative expression of SOD2 mRNA normalized to 18S in normal (n ¼ 8) and glaucomatous (n ¼ 8) ONH astrocyte cultures (n ¼ 8, respectively, two-tailed t test was used. Indicates po0.05). (See Colour Plate 25.8 in the colour plate section.)
(Ferreira et al., 2004) who found 3-fold higher glutathione peroxidase activity in the aqueous humor of patients with glaucoma compared to patients with cataracts. This is further evidence of alterations in antioxidant enzymes in glaucoma.
AKR1C1, an aldo–keto reductase involved in androgen and neurosteroid metabolism, has been shown to be over-expressed in glaucomatous optic nerves, suggesting a constitutive response to chronic oxidative stress (Agapova et al., 2003b). ONH
368
astrocytes upregulate expression AKR1C1 following treatment with HNE, which can inactivate HNE. AKR1C1 acts as a reductase by converting HNE to 1,4-dihydroxy-2-nonene (an inactive metabolite), thereby eliminating the ability of HNE to bind to protein or DNA (Burczynski et al., 2001). Enzymes such as AKR1C1 may play a more important role in the inactivation of HNE when the primary stores of GSH are depleted in the cell, as exhibited immediately following treatment with HNE in normal ONH astrocytes, because AKR1C1 can reduce HNE independent of GSH.
Glial cells protect neurons and are involved in the antioxidant defense in the brain by synthesizing GSH, mostly located in glial cells in the brain (Pearce et al., 1997) and by providing precursors that neurons require to make their own GSH (Sagara et al., 1993; Dringen et al., 1999). Since astrocytes have high levels of antioxidants (Makar et al., 1994; Dringen and Hamprecht, 1997), they can sustain the presence of ROS and therefore prevent their neurotoxicity (Wilson, 1997) which we demonstrated after HNE treatment.
Astrocytes can transport GSH conjugated to HNE out of the cell via the multidrug-resistance protein (MRP1) (Hirrlinger et al., 2002) or through the RLIP76 (Ral binding protein) (Yang et al., 2003). Once outside of the cell, the released GSH cannot be taken up by neurons, so gamma-glutamyl transpeptidase (GGT) present on the plasma membrane of astrocytes cleaves GSH into components that can be further cleaved and taken up by neurons. These basic components are then utilized by the neuron to synthesize GSH (Heales et al., 2004). Therefore, ONH astrocytes may offer neuroprotection in the optic nerve by releasing GSH and antioxidant enzymes to eliminate the products of chronic oxidative stress that may be contributing to the progression of neurodegeneration in POAG.
Conclusions
This review intends to raise many questions that will require future investigations. Astrocytes serve protective and trophic functions to the axons of the retinal ganglion cells in the optic nerve.
Glaucomatous ONH astrocytes share many characteristics of reactive astrocytes in the CNS; certain properties may be specific to the pathophysiology of glaucoma. Our own data indicates that the microenvironment supported by astrocytes in the normal and glaucomatous ONH has characteristics that may impact susceptibility to glaucomatous optic neuropathy in certain individuals. Future directions include identification and characterization of signaling pathways involved in astrocyte function and further exploration on the role of selected identified genes in experimental animal and in vitro models of glaucoma.
Acknowledgments
This work was supported by National Institutes of Health Grant EY-06416 and by National Research to Prevent Blindness (RPB).
References
Abraham, C.R. (2001) Reactive astrocytes and alpha1-anti- chymotrypsin in Alzheimer’s disease. Neurobiol. Aging, 22: 931–936.
Agapova, O.A., Kaufman, P.L. and Hernandez, M.R. (2006a) Androgen receptor and NFkB expression in human normal and glaucomatous optic nerve head astrocytes in vitro and in experimental glaucoma. Exp. Eye Res., 82: 1053–1059.
Agapova, O.A., Kaufman, P.L., Lucarelli, M.J., Gabelt, B.T. and Hernandez, M.R. (2003a) Differential expression of matrix metalloproteinases in monkey eyes with experimental glaucoma or optic nerve transection. Brain Res., 967: 132–143.
Agapova, O.A., Malone, P.E. and Hernandez, M.R. (2006b) A neuroactive steroid 5alpha-androstane-3alpha, 17beta-diol regulates androgen receptor level in astrocytes. J. Neurochem., 98: 355–363.
Agapova, O.A., Yang, P., Wang, W.H., Lane, D.A., Clark, A.F., Weinstein, B.I. and Hernandez, M.R. (2003b) Altered expression of 3alpha-hydroxysteroid dehydrogenases in human glaucomatous optic nerve head astrocytes. Neurobiol. Dis., 14: 63–73.
Ahmed, I., John, A., Vijayasarathy, C., Robin, M.A. and Raza, H. (2002) Differential modulation of growth and glutathione metabolism in cultured rat astrocytes by 4-hydroxynonenal and green tea polyphenol, epigallocatechin-3-gallate. Neurotoxicology, 23: 289–300.
Anderson, C.M. and Swanson, R.A. (2000) Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia, 32: 1–14.
Araque, A., Carmignoto, G. and Haydon, P.G. (2001) Dynamic signaling between astrocytes and neurons. Annu. Rev. Physiol., 63: 795–813.
Asahi, M., Sumii, T., Fini, M.E., Itohara, S. and Lo, E.H. (2001) Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport, 12: 3003–3007.
Asher, R.A., Morgenstern, D.A., Fidler, P.S., Adcock, K.H., Oohira, A., Braistead, J.E., Levine, J.M., Margolis, R.U., Rogers, J.H. and Fawcett, J.W. (2000) Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J. Neurosci., 20: 2427–2438.
Bachoo, R.M., Kim, R.S., Ligon, K.L., Maher, E.A., Brennan, C., Billings, N., Chan, S., Li, C., Rowitch, D.H., Wong, W.H. and DePinho, R.A. (2004) Molecular diversity of astrocytes with implications for neurological disorders. Proc. Natl. Acad. Sci. U.S.A., 101: 8384–8389.
Becker, C.G., Becker, T. and Meyer, R.L. (2001) Increased NCAM-180 immunoreactivity and maintenance of L1 immunoreactivity in injured optic fibers of adult mice. Exp. Neurol., 169: 438–448.
Beggs, H.E., Schahin-Reed, D., Zang, K., Goebbels, S., Nave, K.A., Gorski, J., Jones, K.R., Sretavan, D. and Reichardt, L.F. (2003) FAK deficiency in cells contributing to the basal lamina results in cortical abnormalities resembling congenital muscular dystrophies. Neuron, 40: 501–514.
Bellezza, A.J., Rintalan, C.J., Thompson, H.W., Downs, J.C., Hart, R.T. and Burgoyne, C.F. (2003) Deformation of the lamina cribrosa and anterior scleral canal wall in early experimental glaucoma. Invest. Ophthalmol. Vis. Sci., 44: 623–637.
Bourguignon, L.Y., Gilad, E., Peyrollier, K., Brightman, A. and Swanson, R.A. (2007) Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKN gamma kinase activation leading to cytoskeleton function and cell migration in astrocytes. J. Neurochem., 101: 1002–1017.
Bowman, C.L., Kimelberg, H.K., Frangakis, M.V., BerwaldNetter, Y. and Edwards, C. (1984) Astrocytes in primary culture have chemically activated sodium channels. J. Neurosci., 4: 1527–1534.
Bruzzone, R., White, T.W. and Goodenough, D.A. (1996) The cellular Internet: on-line with connexins. Bioessays, 18: 709–718.
Burczynski, M.E., Sridhar, G.R., Palackal, N.T. and Penning, T.M. (2001) The reactive oxygen species and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha, beta-unsaturated aldehyde 4-hydroxy-2- nonenal to 1,4-dihydroxy-2-nonene. J. Biol. Chem., 276: 2890–2897.
Chachisvilis, M., Zhang, Y.L. and Frangos, J.A. (2006) G protein-coupled receptors sense fluid shear stress in endothelial cells. Proc. Natl. Acad. Sci. U.S.A., 103: 15463–15468.
Charles, P., Hernandez, M.P., Stankoff, B., Aigrot, M.S., Colin, C., Rougon, G., Zalc, B. and Lubetzki, C. (2000) Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc. Natl. Acad. Sci. U.S.A., 97: 7585–7590.
369
Chauhan, B.C., LeVatte, T.L., Jollimore, C.A., Yu, P.K., Reitsamer, H.A., Kelly, M.E., Yu, D.Y., Tremblay, F. and Archibald, M.L. (2004) Model of endothelin-1-induced chronic optic neuropathy in rat. Invest. Ophthalmol. Vis. Sci., 45: 144–152.
Chen, D., Zhao, M. and Mundy, G.R. (2004) Bone morphogenetic proteins. Growth Factors, 22: 233–241.
Chintala, S.K., Zhang, X., Austin, J.S. and Fini, M.E. (2002) Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J. Biol. Chem., 277: 47461–47468.
Clark, I.M., Swingler, T.E., Sampieri, C.L. and Edwards, D.R. (2007) The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol., 40: 1362–1378.
Croisier, E. and Graeber, M.B. (2006) Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol., 112: 517–530.
Cusato, K., Bosco, A., Rozental, R., Guimaraes, C.A., Reese, B.E., Linden, R. and Spray, D.C. (2003) Gap junctions mediate bystander cell death in developing retina. J. Neurosci., 23: 6413–6422.
Dickinson, D.A., Iles, K.E., Watanabe, N., Iwamoto, T., Zhang, H., Krzywanski, D.M. and Forman, H.J. (2002) 4- hydroxynonenal induces glutamate cysteine ligase through JNK in HBE1 cells. Free Radic. Biol. Med., 33: p. 974.
Dringen, R. and Hamprecht, B. (1997) Involvement of glutathione peroxidase and catalase in the disposal of exogenous hydrogen peroxide by cultured astroglial cells. Brain Res., 759: 67–75.
Dringen, R., Pfeiffer, B. and Hamprecht, B. (1999) Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J. Neurosci., 19: 562–569.
Esparza-Lopez, J., Montiel, J.L., Vilchis-Landeros, M.M., Okadome, T., Miyazono, K. and Lopez-Casillas, F. (2001) Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J. Biol. Chem., 276: 14588–14596.
Etienne-Manneville, S. and Hall, A. (2001) Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCzeta. Cell, 106: 489–498.
Feng, Z., Li, L., Ng, P.Y. and Porter, A.G. (2002) Neuronal differentiation and protection from nitric oxide-induced apoptosis require c-Jun-dependent expression of NCAM140. Mol. Cell Biol., 22: 5357–5366.
Ferreira, S.M., Lerner, S.F., Brunzini, R., Evelson, P.A. and Llesuy, S.F. (2004) Oxidative stress markers in aqueous humor of glaucoma patients. Am. J. Ophthalmol., 137: 62–69.
Flanders, K.C., Ren, R.F. and Lippa, C.F. (1998) Transforming growth factor-betas in neurodegenerative disease. Prog. Neurobiol., 54: 71–85.
Fruttiger, M., Calver, A.R., Kruger, W.H., Mudhar, H.S., Michalovich, W.D., Takakura, N., Nishikawa, S. and
370
Richardson, W.D. (1996) PDGF mediates a neuron-astrocyte interaction in the developing retina. Neuron, 17: 1117–1131.
Fuchshofer, R., Birke, M., Welge-Lussen, U., Kook, D. and Lutjen-Drecoll, E. (2005) Transforming growth factor-beta 2 modulated extracellular matrix component expression in cultured human optic nerve head astrocytes. Invest. Ophthalmol. Vis. Sci., 46: 568–578.
Galtrey, C.M. and Fawcett, J.W. (2007) The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res. Rev., 54: 1–18.
Gherghel, D., Griffiths, H.R., Hilton, E.J., Cunliffe, I.A. and Hosking, S.L. (2005) Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci., 46: 877–883.
Giaume, C. and McCarthy, K.D. (1996) Control of gapjunctional communication in astrocytic networks. Trends Neurosci., 19: 319–325.
Goodenough, D.A., Goliger, J.A. and Paul, D.L. (1996) Connexins, connexons, and intercellular communication. Annu. Rev. Biochem., 65: 475–502.
Gris, P., Tighe, A., Levin, D., Sharma, R. and Brown, A. (2007) Transcriptional regulation of scar gene expression in primary astrocytes. Glia, 55: 1145–1155.
Hansson, E. and Ronnback, L. (2003) Glial neuronal signaling in the central nervous system. FASEB J., 17: 341–348.
Hartsough, M.T. and Mulder, K.M. (1997) Transforming growth factor-beta signaling in epithelial cells. Pharmacol. Ther., 75: 21–41.
Hashimoto, K., Parker, A., Malone, P., Gabelt, B.T., Rasmussen, C., Kaufman, P.S. and Hernandez, M.R. (2005) Long-term activation of c-Fos and c-Jun in optic nerve head astrocytes in experimental ocular hypertension in monkeys and after exposure to elevated pressure in vitro. Brain Res., 1054: 103–115.
He, S., Prasanna, G. and Yorio, T. (2007) Endothelin-1- mediated signaling in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in astrocytes. Invest. Ophthalmol. Vis. Sci., 48: 3737–3745.
Heales, S.J., Lam, A.A., Duncan, A.J. and Land, J.M. (2004) Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem. Res., 29: 513–519.
Hernandez, M.R. (2000) The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog. Retin. Eye Res., 19: 297–321.
Hernandez, M.R., Agapova, O.A., Yang, P., Salvador-Silva, M., Ricard, C.S. and Aoi, S. (2002) Differential gene expression in astrocytes from human normal and glaucomatous optic nerve head analyzed by cDNA microarray. Glia, 38: 45–64.
Hernandez, M.R., Igoe, F. and Neufeld, A.H. (1988) Cell culture of the human lamina cribrosa. Invest. Ophthalmol. Vis. Sci., 29: 78–89.
Hernandez, M.R. and Pena, J.D. (1997) The optic nerve head in glaucomatous optic neuropathy. Arch. Ophthalmol., 115: 389–395.
Hernandez, M.R., Pena, J.D., Selvidge, J.A., Salvador-Silva, M. and Yang, P. (2000) Hydrostatic pressure stimulates
synthesis of elastin in cultured optic nerve head astrocytes. Glia, 32: 122–136.
Hewitt, A.W., Craig, J.E. and Mackey, D.A. (2006) Complex genetics of complex traits: the case of primary open-angle glaucoma. Clin. Experiment. Ophthalmol., 34: 472–484.
Himanen, J.P., Saha, N. and Nikolov, D.B. (2007) Cell-cell signaling via Eph receptors and ephrins. Curr. Opin. Cell Biol., 19: 534–542.
Hirrlinger, J., Gutterer, J.M., Kussmaul, L., Hamprecht, B. and Dringen, R. (2000) Microglial cells in culture express a prominent glutathione system for the defense against reactive oxygen species. Dev. Neurosci., 22: 384–392.
Hirrlinger, J., Schulz, J.B. and Dringen, R. (2002) Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J. Neurosci. Res., 69: 318–326.
Hu, R.G., Sheng, J., Qi, X., Xu, Z., Takahashi, T.T. and Varshavsky, A. (2005) The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators. Nature, 437: 981–986.
Ji, B., Ito, K. and Horie, T. (2004) Multidrug resistanceassociated protein 2 (MRP2) enhances 4-hydroxynonenal- induced toxicity in Madin-Darby canine kidney II cells. Chem. Res. Toxicol., 17: 158–164.
Johnson, C.A., Cioffi, G.A., Liebmann, J.R., Sample, P.A., Zangwill, L.M. and Weinreb, R.N. (2000) The relationship between structural and functional alterations in glaucoma: a review. Semin. Ophthalmol., 15: 221–233.
Junier, M.P. (2000) What role(s) for TGFalpha in the central nervous system?. Prog. Neurobiol., 62: 443–473.
Kalman, D., Gomperts, S.N., Hardy, S., Kitamura, M. and Bishop, J.M. (1999) Ras family GTPases control growth of astrocyte processes. Mol. Biol. Cell, 10: 1665–1683.
Kielian, T. and Esen, N. (2004) Effects of neuroinflammation on glia-glia gap junctional intercellular communication: a perspective. Neurochem. Int., 45: 429–436.
Kirwan, R.P., Crean, J.K., Fenerty, C.H., Clark, A.F. and O’Brien, C.J. (2004) Effect of cyclical mechanical stretch and exogenous transforming growth factor-beta1 on matrix metalloproteinase-2 activity in lamina cribrosa cells from the human optic nerve head. J. Glaucoma., 13: 327–334.
Kirwan, R.P., Leonard, M.O., Murphy, M., Clark, A.F. and O’Brien, C.J. (2005) Transforming growth factor-beta- regulated gene transcription and protein expression in human GFAP-negative lamina cribrosa cells. Glia, 52: 309–324.
Koyama, Y., Yoshioka, Y., Hashimoto, H., Matsuda, T. and Baba, A. (2000) Endothelins increase tyrosine phosphorylation of astrocytic focal adhesion kinase and paxillin accompanied by their association with cytoskeletal components. Neuroscience, 101: 219–227.
Lagord, C., Berry, M. and Logan, A. (2002) Expression of TGFbeta2 but not TGFbeta1 correlates with the deposition of scar tissue in the lesioned spinal cord. Mol. Cell Neurosci., 20: 69–92.
Lambert, W.S., Clark, A.F. and Wordinger, R.J. (2004a) Effect of exogenous neurotrophins on Trk receptor phosphorylation, cell proliferation, and neurotrophin secretion by cells
isolated from the human lamina cribrosa. Mol. Vis., 10: 289–296.
Lambert, W.S., Clark, A.F. and Wordinger, R.J. (2004b) Neurotrophin and Trk expression by cells of the human lamina cribrosa following oxygen-glucose deprivation. BMC Neurosci., 5: p. 51.
Lapis, K. and Timar, J. (2002) Role of elastin-matrix interactions in tumor progression. Semin. Cancer Biol., 12: 209–217.
Liu, B., Chen, H., Johns, T.G. and Neufeld, A.H. (2006) Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J. Neurosci., 26: 7532–7540.
Liu, B. and Neufeld, A.H. (2000) Expression of nitric oxide synthase-2 (NOS-2) in reactive astrocytes of the human glaucomatous optic nerve head. Glia, 30: 178–186.
Liu, B. and Neufeld, A.H. (2004) Activation of epidermal growth factor receptor causes astrocytes to form cribriform structures. Glia, 46: 153–168.
Liu, B. and Neufeld, A.H. (2007) Activation of epidermal growth factor receptors in astrocytes: from development to neural injury. J. Neurosci. Res., 85: 3523–3529.
Liu, X., Clark, A.F. and Wordinger, R.J. (2007) Expression of ciliary neurotrophic factor (CNTF) and its tripartite receptor complex by cells of the human optic nerve head. Mol. Vis., 13: 758–763.
Logan, A., Baird, A. and Berry, M. (1999a) Decorin attenuates gliotic scar formation in the rat cerebral hemisphere. Exp. Neurol., 159: 504–510.
Logan, A., Green, J., Hunter, A., Jackson, R. and Berry, M. (1999b) Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-beta2. Eur. J. Neurosci., 11: 2367–2374.
Lu, Z., Lam, K.S., Wang, N., Xu, X., Cortes, M. and Andersen, B. (2006) LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells. Oncogene, 25: 2920–2930.
Lutjen-Drecoll, E. (2005) Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp. Eye Res., 81: 1–4.
Lykissas, M.G., Batistatou, A.K., Charalabopoulos, K.A. and Beris, A.E. (2007) The role of neurotrophins in axonal growth, guidance, and regeneration. Curr. Neurovasc. Res., 4: 143–151.
Magistretti, P.J. (2006) Neuron-glia metabolic coupling and plasticity. J. Exp. Biol., 209: 2304–2311.
Makar, T.K., Nedergaard, M., Preuss, A., Gelbard, A.S., Perumal, A.S. and Cooper, A.J. (1994) Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain. J. Neurochem., 62: 45–53.
Malone, P., Miao, H., Parker, A., Juarez, S. and Hernandez, M.R. (2007) Pressure induces loss of gap junction communication and redistribution of connexin 43 in astrocytes. Glia, 55: 1085–1098.
Malone, P.E. and Hernandez, M.R. (2007) 4-Hydroxynonenal, a product of oxidative stress, leads to an antioxidant response in optic nerve head astrocytes. Exp. Eye Res., 84: 444–454.
371
Mandell, J.W., Gocan, N.C. and Vandenberg, S.R. (2001) Mechanical trauma induces rapid astroglial activation of ERK/MAP kinase: evidence for a paracrine signal. Glia, 34: 283–295.
Maness, P.F. and Schachner, M. (2007) Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat. Neurosci., 10: 19–26.
McKeon, R.J., Jurynec, M.J. and Buck, C.R. (1999) The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. J. Neurosci., 19: 10778–10788.
Moreno, A.P., Rook, M.B., Fishman, G.I. and Spray, D.C. (1994) Gap junction channels: distinct voltage-sensitive and insensitive conductance states. Biophys. J., 67: 113–119.
Morrison, J.C. (2006) Integrins in the optic nerve head: potential roles in glaucomatous optic neuropathy (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc., 104: 453–477.
Nagy, J.I., Dudek, F.E. and Rash, J.E. (2004) Update on connexins and gap junctions in neurons and glia in the mammalian nervous system. Brain Res. Brain Res. Rev., 47: 191–215.
Netland, P.A., Ye, H., Streeten, B.W. and Hernandez, M.R. (1995) Elastosis of the lamina cribrosa in pseudoexfoliation syndrome with glaucoma. Ophthalmology, 102: 878–886.
Neufeld, A.H. and Liu, B. (2003) Comparison of the signal transduction pathways for the induction of gene expression of nitric oxide synthase-2 in response to two different stimuli. Nitric Oxide, 8: 95–102.
Obara, M., Szeliga, M. and Albrecht, J. (2008) Regulation of pH in the mammalian central nervous system under normal and pathological conditions: facts and hypotheses. Neurochem. Int., 52: 905–919.
Oelze, I., Kartenbeck, J., Crusius, K. and Alonso, A. (1995) Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line. J. Virol., 69: 4489–4494.
Osmani, N., Vitale, N., Borg, J.P. and Etienne-Manneville, S. (2006) Scrib controls Cdc42 localization and activity to promote cell polarization during astrocyte migration. Curr. Biol., 16: 2395–2405.
Pearce, R.K., Owen, A., Daniel, S., Jenner, P. and Marsden, C.D. (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J. Neural Transm., 104: 661–677.
Pehar, M., Vargas, M.R., Cassina, P., Barbeito, A.G., Beckman, J.S. and Barbeito, L. (2005) Complexity of astrocytemotor neuron interactions in amyotrophic lateral sclerosis. Neurodegener. Dis., 2: 139–146.
Pena, J.D., Agapova, O., Gabelt, B.T., Levin, L.A., Lucarelli, M.J., Kaufman, P.L. and Hernandez, M.R. (2001) Increased elastin expression in astrocytes of the lamina cribrosa in response to elevated intraocular pressure. Invest. Ophthalmol. Vis. Sci., 42: 2303–2314.
Pena, J.D., Taylor, A.W., Ricard, C.S., Vidal, I. and Hernandez, M.R. (1999a) Transforming growth factor beta
372
isoforms in human optic nerve heads. Br. J. Ophthalmol., 83: 209–218.
Pena, J.D., Varela, H.J., Ricard, C.S. and Hernandez, M.R. (1999b) Enhanced tenascin expression associated with reactive astrocytes in human optic nerve heads with primary open angle glaucoma. Exp. Eye Res., 68: 29–40.
Prasanna, G., Krishnamoorthy, R., Clark, A.F., Wordinger, R.J. and Yorio, T. (2002) Human optic nerve head astrocytes as a target for endothelin-1. Invest. Ophthalmol. Vis. Sci., 43: 2704–2713.
Rao, V.R., Krishnamoorthy, R.R. and Yorio, T. (2007) Endothelin-1, endothelin A and B receptor expression and their pharmacological properties in GFAP negative human lamina cribrosa cells. Exp. Eye Res., 84: 1115–1124.
Ricard, C.S., Kobayashi, S., Pena, J.D., Salvador-Silva, M., Agapova, O. and Hernandez, M.R. (2000) Selective expression of neural cell adhesion molecule (NCAM)-180 in optic nerve head astrocytes exposed to elevated hydrostatic pressure in vitro. Brain Res. Mol. Brain Res., 81: 62–79.
Ridet, J.L., Malhotra, S.K., Privat, A. and Gage, F.H. (1997) Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci., 20: 570–577.
Rose, C.R. and Ransom, B.R. (1997) Gap junctions equalize intracellular Na+ concentration in astrocytes. Glia, 20: 299–307.
Rusnati, M. and Presta, M. (2007) Fibroblast growth factors/ fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr. Pharm. Des., 13: 2025–2044.
Sagara, J.I., Miura, K. and Bannai, S. (1993) Maintenance of neuronal glutathione by glial cells. J. Neurochem., 61: 1672–1676.
Salvador-Silva, M., Aoi, S., Parker, A., Yang, P., Pecen, P. and Hernandez, M.R. (2004) Responses and signaling pathways in human optic nerve head astrocytes exposed to hydrostatic pressure in vitro. Glia, 45: 364–377.
Salvador-Silva, M., Ricard, C.S., Agapova, O.A., Yang, P. and Hernandez, M.R. (2001) Expression of small heat shock proteins and intermediate filaments in the human optic nerve head astrocytes exposed to elevated hydrostatic pressure in vitro. J. Neurosci. Res., 66: 59–73.
Sawada, Y., Tamada, M., Dubin-Thaler, B.J., Cherniavskaya, O., Sakai, R., Tanaka, S. and Sheetz, M.P. (2006) Force sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell, 127: 1015–1026.
Seachrist, J.L. and Ferguson, S.S. (2003) Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases. Life Sci., 74: 225–235.
Smith, C., Berry, M., Clarke, W.E. and Logan, A. (2001) Differential expression of fibroblast growth factor-2 and fibroblast growth factor receptor 1 in a scarring and nonscarring model of CNS injury in the rat. Eur. J. Neurosci., 13: 443–456.
Tait, M.J., Saadoun, S., Bell, B.A. and Papadopoulos, M.C. (2008) Water movements in the brain: role of aquaporins. Trends Neurosci., 31: 37–43.
Tezel, G. (2006) Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin. Eye Res., 25: 490–513.
Tezel, G., Chauhan, B.C., LeBlanc, R.P. and Wax, M.B. (2003) Immunohistochemical assessment of the glial mitogen-acti- vated protein kinase activation in glaucoma. Invest. Ophthalmol. Vis. Sci., 44: 3025–3033.
Tezel, G., Hernandez, M.R. and Wax, M.B. (2001) In vitro evaluation of reactive astrocyte migration, a component of tissue remodeling in glaucomatous optic nerve head. Glia, 34: 178–189.
Tezel, G., Yang, X., Yang, J. and Wax, M.B. (2004) Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice. Brain Res., 996: 202–212.
Thorleifsson, G., Magnusson, K.P., Sulem, P., Walters, G.B., Gudbjartsson, D.F., Stefansson, H., Jonsson, T., Jonasdottir, A., Jonasdottir, A., Stefansdottir, G., Masson, G., Hardarson, G.A., Petursson, H., Arnarsson, A., Motallebipour, M., Wallerman, O., Wadelius, C., Gulcher, J.R., Thorsteinsdottir, U., Kong, A., Jonasson, F. and Stefansson, K. (2007) Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science, 317: 1397–1400.
Tichauer, J., Saud, K. and von Bernhardi, R. (2007) Modulation by astrocytes of microglial cell-mediated neuroinflammation: effect on the activation of microglial signaling pathways. Neuroimmunomodulation, 14: 168–174.
Urban, Z., Agapova, O., Hucthagowder, V., Yang, P., Starcher, B.C. and Hernandez, M.R. (2007) Population differences in elastin maturation in optic nerve head tissue and astrocytes. Invest. Ophthalmol. Vis. Sci., 48: 3209–3215.
Varela, H.J. and Hernandez, M.R. (1997) Astrocyte responses in human optic nerve head with primary open-angle glaucoma. J. Glaucoma., 6: 303–313.
Wang, L., Fortune, B., Cull, G., Dong, J. and Cioffi, G.A. (2006) Endothelin B receptor in human glaucoma and experimentally induced optic nerve damage. Arch. Ophthalmol., 124: 717–724.
Wang, X., Mori, T., Jung, J.C., Fini, M.E. and Lo, E.H. (2002) Secretion of matrix metalloproteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. J. Neurotrauma., 19: 615–625.
Warn-Cramer, B.J., Cottrell, G.T., Burt, J.M. and Lau, A.F. (1998) Regulation of connexin-43 gap junctional intercellular communication by mitogen-activated protein kinase. J. Biol. Chem., 273: 9188–9196.
Wax, M.B., Tezel, G., Kobayashi, S. and Hernandez, M.R. (2000) Responses of different cell lines from ocular tissues to elevated hydrostatic pressure. Br. J. Ophthalmol., 84: 423–428.
Weinreb, R.N. and Khaw, P.T. (2004) Primary open-angle glaucoma. Lancet, 363: 1711–1720.
Wheeler, A.P., Wells, C.M., Smith, S.D., Vega, F.M., Henderson, R.B., Tybulewicz, V.L. and Ridley, A.J. (2006) Rac1 and Rac2 regulate macrophage morphology but are not essential for migration. J. Cell Sci., 119: 2749–2757.
Wieduwilt, M.J. and Moasser, M.M. (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol. Life Sci., 65: 1566–1584.
Wiggs, J.L. (2007) Genetic etiologies of glaucoma. Arch. Ophthalmol., 125: 30–37.
Wilson, J.X. (1997) Antioxidant defense of the brain: a role for astrocytes. Can. J. Physiol. Pharmacol., 75: 1149–1163.
Wordinger, R.J., Agarwal, R., Talati, M., Fuller, J., Lambert, W. and Clark, A.F. (2002) Expression of bone morphogenetic proteins (BMP), BMP receptors, and BMP associated proteins in human trabecular meshwork and optic nerve head cells and tissues. Mol. Vis., 8: 241–250.
Yang, P., Agapova, O., Parker, A., Shannon, W., Pecen, P., Duncan, J., Salvador-Silva, M. and Hernandez, M.R. (2004) DNA microarray analysis of gene expression in human optic nerve head astrocytes in response to hydrostatic pressure. Physiol. Genomics, 17: 157–169.
Yang, P. and Hernandez, M.R. (2003) Purification of astrocytes from adult human optic nerve heads by immunopanning. Brain Res. Brain Res. Protoc., 12: 67–76.
373
Yang, Y., Sharma, R., Sharma, A., Awasthi, S. and Awasthi, Y.C. (2003) Lipid peroxidation and cell cycle signaling: 4- hydroxynonenal, a key molecule in stress mediated signaling. Acta. Biochim. Pol., 50: 319–336.
Yu, A.L., Fuchshofer, R., Birke, M., Priglinger, S.G., Eibl, K.H., Kampik, A., Bloemendal, H. and Welge-Lussen, U. (2007) Hypoxia/reoxygenation and TGF-beta increase alphaB-crystallin expression in human optic nerve head astrocytes. Exp. Eye Res., 84: 694–706.
Zhang, H., Uchimura, K. and Kadomatsu, K. (2006) Brain keratan sulfate and glial scar formation. Ann. N.Y. Acad. Sci., 1086: 81–90.
Zhao, X., Ramsey, K.E., Stephan, D.A. and Russell, P. (2004) Gene and protein expression changes in human trabecular meshwork cells treated with transforming growth factor-beta. Invest. Ophthalmol. Vis. Sci., 45: 4023–4034.
Zode, G.S., Clark, A.F. and Wordinger, R.J. (2007) Activation of the BMP canonical signaling pathway in human optic nerve head tissue and isolated optic nerve head astrocytes and lamina cribrosa cells. Invest. Ophthalmol. Vis. Sci., 48: 5058–5067.
